Ajanta Pharma promoter creates pledge on 1.11 million shares for new loan

What Ajanta Pharma announced

Ajanta Pharma Ltd (BSE: 532331, NSE: AJANTPHARM) disclosed that its promoter, Aayush Agrawal, acting as trustee of the Aayush Agrawal Trust, created a pledge over 1,111,111 shares of the company. The pledge is intended as collateral for a new loan. The promoter submitted the required form under SEBI (SAST) Regulations 31(1) and 31(2) on 12 June 2026, and the exchange recorded the filing on 15 June 2026.

Details of the pledge creation

• Promoter/Trustee: Aayush Agrawal, trustee of Aayush Agrawal Trust.
• Number of shares pledged: 1,111,111 shares (written as 11,11,111 in the filing).
• Purpose: Securing a new loan for the promoter.
• Date of creation: 10 June 2026 (as indicated in the tabular summary of encumbrances).
• Reporting date: 12 June 2026; filing date with the exchanges: 15 June 2026.
• Regulatory basis: Disclosure under Regulation 31(1) and 31(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Shareholding context

The filing also lists the promoter’s overall holding in Ajanta Pharma:

• Total promoter holding: 1,41,12,924 shares, representing 11.30 % of the company’s total share capital.
• Pledged portion: 1,111,111 shares, which is roughly 0.79 % of the promoter’s total holding and about 0.09 % of the company’s total equity (based on the disclosed share capital).
• Other promoters (Yogesh M. Agrawal, Rajesh M. Agrawal, Ravi P. Agrawal, etc.) also disclosed pledged shares, but the primary focus of this filing is the pledge by Aayush Agrawal Trust.

Key facts at a glance

Why this matters for investors

The creation of a pledge on promoter shares is a material event under SEBI’s SAST framework because it places a portion of the promoter’s equity as collateral. For shareholders, the key implications are:

• Potential dilution risk: If the loan defaults, the pledged shares could be transferred to the lender, altering the promoter’s voting power.
• Transparency: The filing satisfies regulatory requirements, ensuring that the market is aware of encumbrances on promoter holdings.
• Financial leverage: The pledge indicates that the promoter is raising external financing, which may affect the company’s broader capital structure, although the loan is personal to the promoter and not directly on the company’s balance sheet.
• No immediate impact on share price: The disclosure is informational; any price movement would depend on subsequent actions by the lender or changes in the promoter’s shareholding.

Conclusion

Ajanta Pharma’s promoter, Aayush Agrawal Trust, pledged 1.11 million shares on 10 June 2026 to secure a new loan, with the disclosure filed on 15 June 2026 under SEBI’s SAST regulations. The pledge represents a small fraction of the promoter’s overall holding and, while it introduces a potential future change in share ownership, no further corporate action is required at this stage.